Unveiling the future of age reversal: meet Yuri Deigin, founder of YouthBio Therapeutics
Longevity Technology - 08-Mar-2023Tissue-specific gene therapies & rejuvenating factors to extend lifespan and combat age-related diseases
Yuri Deigin
Co-founder and Director at YouthBio Therapeutics
Yuri is a biotech entrepreneur with a focus on early-stage translation of scientific breakthroughs into therapies. He has over a decade of drug discovery and development experience, and a track record of outlicensing products to Big Pharma.
Yuri has previously led several early-stage pharmaceutical startups, including one developing an Alzheimer's Disease therapeutic, and another startup developing small-molecule neuroprotectors for Alzheimer's, Parkinson's, and a rare pediatric disease.
Additionally, Yuri has been a vocal evangelist of epigenetic rejuvenation by partial reprogramming with Yamanaka factors since 2017.
Visit website: https://youthbiotx.com/#yuri
See also: 
YouthBio Therapeutics
- Developing rejuvenation gene therapies based on partial reprogramming by Yamanaka factors
Details last updated 02-Apr-2022
Yuri Deigin is also referenced in the following:
Longevity Summit Dublin 2023
17-Aug-2023 to 20-Aug-2023
Club discount available - click here
Event gathering Global Longevity and Rejuvenation community in Dublin with many longevity movement superstars as speakers
New discovery: we can reprogram cells to become younger! Yuri Deigin
Yuri Deigin discusses reprogramming cells to reverse ageing
YouthBio Therapeutics
Developing rejuvenation gene therapies based on partial reprogramming by Yamanaka factors
Yuri Deigin | Epigenetic Reprogramming, Cryonics & COVID Lab Leak
Live Longer World podcast #17 with Yuri Deigin as a guest
Yuri Deigin News
Reason reports back from October's Rejuvenation Startup Summit
Fight Aging! - 19-Oct-2022Some really exciting developments with quite a few in clinical trials
YouthBio Therapeutics unveils its board, with João Pedro de Magalhães as CSO
CISION PR Newswire - 14-Apr-2022Another company enters the cellular reprogramming race - hopefully at least one will cross the finishing line
